Trial Profile
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Aceclidine/tropicamide (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors LENZ Therapeutics
- 28 Aug 2018 Status changed from recruiting to completed.
- 30 Jul 2018 Primary endpoint of (Proportion of subjects with at least a 3 line (15 letter) improvement in the study eye) has been met, according to a Presbyopia Therapies media release.
- 30 Jul 2018 Results presented in the Presbyopia Therapies media release.